Hemispherian: Developing new ways to fight cancer
About the project
Hemispherian is developing innovative cancer treatments that target how cancer cells repair themselves, without harming healthy cells. Its main focus is glioblastoma multiforme, an aggressive brain cancer that often affects younger people and currently has very few effective treatment options.
Since late 2022, Hemispherian has secured NOK 140 million (roughly USD 13.3 million) in funding, including NOK 105 million (roughly USD 10 million) from the European Innovation Council (EIC Accelerator). The company is now working to attract investment from the United States to further advance its research and expand its international partnerships.
How Invest in Norway helped
Innovation Norway’s New York team has worked closely with Hemispherian’s leadership to connect them with both US and European investors. This has involved extensive outreach, leading to over 20 meetings with investors, some of whom are now conducting in-depth evaluations of the company.
“Hemispherian receives indispensable support from Innovation Norway. Jannik Schmidt and the health team in New York introduce us to investors and key figures in the US pharmaceutical industry, helping us to move our vision forward. ”
Zeno Albisser
Founder & CEO of Hemispherian
- JS
Jannik Grodt Schmidt
Investment Manager | USA
Health and life science
Take a deep dive into Norway’s health and life science industry
Norway offers pioneering health solutions, with particular strengths in biopharma, radiopharma, medtech and digital health. Click to read articles, discover solution providers and find events where you can meet Norwegian companies.
